AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 42 min read$DRTS

Levy Raphi sold $191K of DRTS

Levy Raphi (Chief Financial Officer) sold 17,500 shares of Alpha Tau Medical Ltd. (DRTS) at $10.90 ($0.19M total) on 2026-06-03.

Original reporting
SEC EDGAR · Levy Raphi
Published Jun 4, 2026, 6:29 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 4, 2026, 6:34 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$DRTS
Neutral
medium confidence
Mentioned
$DRTS
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DRTSNeutralLow
01

Why it matters

The disclosure updates insider ownership and can marginally affect sentiment, but it does not provide new fundamental information about trials, revenue, or guidance.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a sustained repricing.

03

What to watch

The article does not state sale rationale, whether other insiders sold/bought, or whether the company has upcoming catalysts; without that, signal-to-noise is low.

Relevance 6/10Novelty 6/10Timing: Filed June 4; sale executed June 3.

Background

The article is an SEC Form 4 insider transaction disclosure for Alpha Tau Medical Ltd. (DRTS).

Company-level read

Ticker impact

$DRTSNeutralMedium confidence
Context

Alpha Tau Medical CFO Levy Raphi sold 17,500 shares in an open-market transaction disclosed via SEC Form 4 on June 3.

Expected impact

Likely limited near-term impact; any effect is more sentiment/positioning than fundamentals.

Evidence & confidence

The filing is an ownership-change disclosure (Form 4) with no accompanying company-specific operational or financial news, and the sale is not described as part of a 10b5-1 plan.

Market effects

Sector

Minimal; this is company-specific insider activity with no sector-wide regulatory/clinical catalyst mentioned.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

A single CFO sale can be routine liquidity/portfolio management and may not reflect a change in business outlook.

Key entities

  • issuer
    Alpha Tau Medical Ltd.

    Subject of the SEC Form 4 insider transaction disclosure (DRTS).

  • insider
    Levy Raphi

    Chief Financial Officer who sold 17,500 shares on June 3.

Read at source← All news

Related articles

JUL 15
$DRTSMed

Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center

Alpha Tau Medical Ltd. (Nasdaq: DRTS) said Banner MD Anderson Cancer Center treated the first immunocompromised patient in its ADMIRE trial of intratumoral Alpha DaRT for recurrent cutaneous squamous cell carcinoma. ADMIRE is a prospective, open-label, single-arm study enrolling up to 28 patients, with objective response rate as the primary endpoint.

manilatimes.net4 min
JUN 23
$DRTSMed

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel

Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) said it treated the first recurrent glioblastoma patient in Israel and the first outside the U.S. with its Alpha DaRT® system at Hadassah University Medical Center in Jerusalem. The company said the minimally invasive stereotactic procedure used a brain applicator and was completed without unexpected complications under the ALL protocol.

manilatimes.net3 min
JUN 4
$DRTSMedAI 9/10

Alpha Tau And Tolmar Form Strategic Collaboration In U.S. Prostate Cancer

Alpha Tau Medical (DRTS) and Tolmar International announced a U.S. collaboration to develop and commercialize Alpha DaRT for prostate cancer. Tolmar will have exclusive U.S. commercialization rights for 20 years from first sale, with an option to expand to bladder cancer after milestones. Tolmar will invest $15m in manufacturing, add $20m equity at $11.99/share, and pay up to $161.5m in milestones; Alpha Tau will supply product at 60% of onward net sales.

rttnews.com4 min